MAIA

MAIA Biotechnology

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 1

Sell signal 0

EPS Beats Expectation

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About MAIA

Maia Biotechnology, Inc.

A clinical stage biotechnology company that developing therapies for non-small cell lung cancer

Industry

Pharmaceutical

Established Date

08/03/2018

Listing Date

07/28/2022

Exchange

American Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.maiabiotech.com

Security Type

Common stock

Office address

444 West Lake Street, Suite 1700, Chicago, IL 60606

Business

Introduction

MAIA Biotechnology, Inc., was incorporated in Delaware on August 3, 2018. The company is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The company's main asset, THIO, is an investigational dual mechanism of action drug candidate that combines telomere targeting and immunogenicity. THIO is a telomere targeting agent currently in clinical development to evaluate its activity in NSCLC. THIO is being developed as a second-line or follow-up treatment line for NSCLC for patients whose treatment progresses beyond the existing standard regimen of checkpoint inhibitors. The company's THIO project has led to the company's second-generation telomere targeting agent development pipeline. The company has launched an early stage research and discovery program aimed at identifying new compounds that can act through an active mechanism similar to THIO, such as targeting and modifying the telomere structure of cancer cells through telomerase activity inherent in cancer cells. The company's current pipeline of second-generation potential telomeric targeting agents includes five compounds that have been successfully tested for in vitro inhibition in five cancer models.

Company Financials

EPS

MAIA has released its 2024 Q4 earnings. EPS was reported at -0.32, versus the expected -0.35, beating expectations. The chart below visualizes how MAIA has performed over recent quarters, highlighting trends in earnings surprises.